Special Issue Article
Beyond First-Line Therapy: Combining Chemotherapy and Radioembolization for Hepatic Colorectal MetastasesJoshua E. Meyer and Steven J. Cohen*
Departments of Radiation Oncology and Medical Oncology Fox Chase Cancer Center
- *Corresponding Author:
- Steven J. Cohen
Departments of Radiation Oncology
and Medical Oncology Fox Chase Cancer Center
333 Cottman Avenue Room C303 Philadelphia, PA 19111-2497
E-mail: [email protected]
Received date: April 26, 2011; Accepted date: May 26, 2011; Published date: June 15, 2011
Citation: Meyer JE, Cohen SJ (2011) Beyond First-Line Therapy: Combining Chemotherapy and Radioembolization for Hepatic Colorectal Metastases. J Nucl Med Radiat Ther 2:103. doi:10.4172/2155-9619.1000103
Copyright: © 2011 Meyer JE, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Metastatic colorectal cancer (mCRC) remains largely an incurable condition. Although progress has been made in expanding the number of available systemic agents, treatment after initial therapy has limited benefit. Radioembolization (RE) with radiolabeled microspheres is an emerging treatment modality for mCRC. Given the potential benefit of chemotherapy to control systemic disease and act as a radiosensitizer, there is high enthusiasm for studying RE and chemotherapy combinations, particularly after initial systemic therapy for patients with liver dominant or confined disease. This manuscript reviews the rationale for this approach, summarizes recently reported clinical trials, and provides a perspective for everyday practice and future unanswered research questions.